menu
    • menu
    [{"orgOrder":0,"company":"Harrow","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Apraclonidine Hydrochloride","moa":"Adrenergic receptor alpha-2A","graph1":"Ophthalmology","graph2":"Approved","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Harrow \/ Harrow Health","highestDevelopmentStatusID":"12","companyTruncated":"Harrow \/ Harrow Health"},{"orgOrder":0,"company":"Harrow","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Apraclonidine Hydrochloride","moa":"Adrenergic receptor alpha","graph1":"Ophthalmology","graph2":"Approved","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Harrow \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Harrow \/ Not Applicable"},{"orgOrder":0,"company":"Harrow","sponsor":"iOR Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Midazolam","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Harrow \/ iOR Partners","highestDevelopmentStatusID":"12","companyTruncated":"Harrow \/ iOR Partners"},{"orgOrder":0,"company":"Harrow","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Nepafenac","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Harrow","amount2":0.13,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.13,"dosageForm":"Suspension\/Drops","sponsorNew":"Harrow \/ Novartis","highestDevelopmentStatusID":"12","companyTruncated":"Harrow \/ Novartis"},{"orgOrder":0,"company":"Harrow","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Fluorometholone Acetate","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Harrow \/ Harrow Health","highestDevelopmentStatusID":"12","companyTruncated":"Harrow \/ Harrow Health"},{"orgOrder":0,"company":"Harrow","sponsor":"Novaliq","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"Cyclosporine","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Harrow \/ Harrow Health","highestDevelopmentStatusID":"12","companyTruncated":"Harrow \/ Harrow Health"},{"orgOrder":0,"company":"Harrow","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Moxifloxacin Hydrochloride","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Harrow \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Harrow \/ Not Applicable"},{"orgOrder":0,"company":"Harrow","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Fluorometholone Acetate","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Harrow \/ Harrow","highestDevelopmentStatusID":"12","companyTruncated":"Harrow \/ Harrow"},{"orgOrder":0,"company":"Harrow","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Cyclosporine","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Emulsion","sponsorNew":"Harrow \/ Apotex Inc.","highestDevelopmentStatusID":"12","companyTruncated":"Harrow \/ Apotex Inc."},{"orgOrder":0,"company":"Harrow","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Triamcinolone Acetonide","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Harrow","amount2":0.13,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0.13,"dosageForm":"Suspension","sponsorNew":"Harrow \/ Harrow","highestDevelopmentStatusID":"12","companyTruncated":"Harrow \/ Harrow"},{"orgOrder":0,"company":"Harrow","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Harrow \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Harrow \/ Not Applicable"},{"orgOrder":0,"company":"Harrow","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Triamcinolone Acetonide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Harrow \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Harrow \/ Not Applicable"},{"orgOrder":0,"company":"Harrow","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Cyclosporine","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Harrow \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Harrow \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Harrow

    Menu

    Harrow

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Harrow

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Harrow

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cyclosporine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Harrow Announces Market Access Wins for VEVYE®

                            Details : Vevye is an approved cyclosporine ophthalmic solution, designed to address unmet needs, providing patients with a fast acting and well tolerable dry eye drug therapy.

                            Brand Name : Vevye

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            November 12, 2024

                            Lead Product(s) : Cyclosporine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Harrow

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Harrow

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Triamcinolone Acetonide

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Harrow Relaunches Triesence®

                            Details : Triesence is an injectable suspension containing triamcinolone acetonide, a synthetic corticosteroid, which is indicated for the treatment of sympathetic ophthalmia, temporal arteritis & uveitis.

                            Brand Name : Triesence

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 03, 2024

                            Lead Product(s) : Triamcinolone Acetonide

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Harrow

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Harrow

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cyclosporine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study

                            Details : Vevye is an approved cyclosporine ophthalmic solution, designed to address unmet needs, providing patients with a fast acting and well tolerable dry eye drug therapy.

                            Brand Name : Vevye

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            June 05, 2024

                            Lead Product(s) : Cyclosporine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Harrow

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Harrow

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cyclosporine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Apotex Inc

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Harrow Licenses Canadian Rights to Apotex for Five Ophthalmic Products

                            Details : Through a licensing agreement, Apotex will market Verkazia (cyclosporine) ophthalmic emulsion, a calcineurin inhibitor indicated for treating vernal keratoconjunctivitis in children and adults.

                            Brand Name : Verkazia

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 15, 2024

                            Lead Product(s) : Cyclosporine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Apotex Inc

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Harrow

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Harrow

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Triamcinolone Acetonide

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Approved

                            Recipient : Novartis Pharmaceuticals Corporation

                            Deal Size : $130.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Harrow Completes Transfer of the TRIESENCE® New Drug Application

                            Details : Harrow diversified its portfolio of branded pharmaceutical products by acquiring 5 ophthalmic products, Ilevro, Nevanac, Vigamox, Maxidex, and Triesence. Triamcinolone acetonide is a synthetic corticosteroid indicated for sympathetic ophthalmia, temporal...

                            Brand Name : Triesence

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 29, 2023

                            Lead Product(s) : Triamcinolone Acetonide

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Approved

                            Recipient : Novartis Pharmaceuticals Corporation

                            Deal Size : $130.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Harrow

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Harrow

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluorometholone Acetate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Recipient : Santen Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® ...

                            Details : Through acquisition, Harrow expands its ophthalmic portfolio by gaining certain U.S. and Canadian commercial rights for Flarex (fluorometholone acetate), Natacyn (natamycin), Tobradex ST (tobramycin and dexamethasone), Verkazia (cyclosporine) and Cationo...

                            Brand Name : Flarex

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 24, 2023

                            Lead Product(s) : Fluorometholone Acetate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Recipient : Santen Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Harrow

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Harrow

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Moxifloxacin Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Harrow Launches VIGAMOX in the U.S.

                            Details : VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) is a fluoroquinolone antibiotic eye drop approved for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.

                            Brand Name : Vigamox

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 31, 2023

                            Lead Product(s) : Moxifloxacin Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Harrow

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Harrow

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluorometholone Acetate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Recipient : Santen Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Harrow Acquires Santen’s Branded Ophthalmic Portfolio

                            Details : Through acquisition, Harrow expands its ophthalmic portfolio by gaining certain U.S. and Canadian commercial rights for Flarex (fluorometholone acetate), Natacyn (natamycin), Tobradex ST (tobramycin and dexamethasone), Verkazia (cyclosporine) and Cationo...

                            Brand Name : Flarex

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 17, 2023

                            Lead Product(s) : Fluorometholone Acetate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Recipient : Santen Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Harrow

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Harrow

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cyclosporine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Recipient : Novaliq

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from No...

                            Details : Through acquisition, Harrow gains U.S. and Canadian commercial rights for Vevye (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, ophthalmic solution prescription drug based on Novaliq’s proprietary EyeSol® water-free technology.

                            Brand Name : Vevye

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            July 17, 2023

                            Lead Product(s) : Cyclosporine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Recipient : Novaliq

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Harrow

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Harrow

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nepafenac

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $130.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Wil...

                            Details : Ilevro (nepafenac) is a non-steroidal anti-inflammatory drug (NSAID). It stops the body from making chemicals that cause inflammation, which helps lessen pain and swelling in the eye due to surgery.

                            Brand Name : Ilevro

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 23, 2023

                            Lead Product(s) : Nepafenac

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Novartis Pharmaceuticals Corporation

                            Deal Size : $130.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth